行情中心 沪深京A股 上证指数 板块行情 股市异动 股圈 专题 涨跌情报站 盯盘 港股 研究所 直播 股票开户 智能选股
全球指数
数据中心 资金流向 龙虎榜 融资融券 沪深港通 比价数据 研报数据 公告掘金 新股申购 大宗交易 业绩速递 科技龙头指数

SHENGYI TECH(600183):DECENT 3Q RESULTS SHENGYI SHOULD RIDE CCL RECOVERY TAILWIND; UPGRADE TO BUY

招银国际证券有限公司 2023-10-29

Shengyi released its 3Q results. Revenue was RMB4,467mn with YoY growth of 3.8% growth and QoQ growth of 8.3%. Net profit was RMB344mn with YoY growth of 31.6% and QoQ growth of 12.0%. GPM expanded from 19.7%/18.9% in 1Q23/2Q23 to 20.0% in 3Q23, and its NPM expanded from 6.6%/7.4% in 1Q23/2Q23 to 7.7% in 3Q23. We see Shengyi is poised to enjoy the recovery in the CCL sector given its leading position and broader end market exposure. We upgrade Shengyi to BUY, with TP adjusted to RMB20.4. But we maintain Shennan at HOLD as we think PCB recovery is slower than CCL.

Decent 3Q results. We observed that the Company's downstream customers have nearly completed their destocking goals, and there is an accelerated recovery in overall demand during 3Q, possibly marking the beginning of a new restocking cycle. Notably, we have witnessed a surge in demand, particularly in the auto and mobile sectors, which have boosted the Company's CCL sales. Furthermore, compared to its industry peers, the Company has solidified its position as an industry leader, evidenced by its consistently higher utilization rates and nearly full CCL capacity utilization since mid-2023. Finally, the Company’s NPM has showed positive progress in the last two quarters.

By segment: 1) CCL revenue was close to RMB3.6bn in 3Q (c.80% of total sales). CCL sales grew roughly 10% QoQ in the past two quarters, confirming a better recovery in the CCL industry. 2) PCB revenue was RMB808mn in 3Q (18% of total sales), decreasing by 7.8% YoY and 3.9% QoQ, suggesting near-term challenges for the industry. In terms of GPM, PCB segment deteriorated further from 18.3%/16.4% in 1Q/2Q23 to 14.2% in 3Q23, while overall GPM improved from 18.9% in 2Q to 20.0% in 3Q, indicating improving GPM for CCL segment.

Upgrade to BUY, with TP adjusted to RMB20.4, based on higher 22.5x 2024E P/E multiple (vs. previous 20x). We believe the valuation is justified considering NP CAGR of 23% over 2022-25E. Potential downside risks include: 1) worse-than-expected macro environment recovery, 2) continuous ASP pressure, and 3) increasing upstream material costs.

免责声明

以上内容仅供您参考和学习使用,任何投资建议均不作为您的投资依据;您需自主做出决策,自行承担风险和损失。九方智投提醒您,市场有风险,投资需谨慎。

推荐阅读

相关股票

相关板块

  • 板块名称
  • 最新价
  • 涨跌幅

相关资讯

扫码下载

九方智投app

扫码关注

九方智投公众号

头条热搜

涨幅排行榜

  • 上证A股
  • 深证A股
  • 科创板
  • 排名
  • 股票名称
  • 最新价
  • 涨跌幅
  • 股圈